http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-0205997-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b141e755084d6f62734f0e211099ef78 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 |
| filingDate | 2002-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b372e16e7ec388991b409ca763bb0dda |
| publicationDate | 2004-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-0205997-A |
| titleOfInvention | New therapeutic application modality to thalidomide used in chronic toxoplasmosis |
| abstract | "NEW MODALITY OF THERAPEUTIC APPLICATION TO THALIDOMIDE USED IN CHRONIC TOXOPLASMOSIS". The current approach to toxoplasmosis considers the existence of congenital toxoplasmosis acquired in the acute phase and reactivation in the immunosuppressed. Specific IgM is used for the diagnosis and parameter for treatment in "immunocompetents". The presence of specific IgG is considered as a sign of latent disease or untreated immunity. In this context there is no room for chronic phase of the disease. However, toxoplasmosis is an autoimmune disease, that is, it presents chronically high levels of cytokines that induce lymphadenopathy, arthralgia / arthritis / bone pain, osteoporosis, cardiovascular changes, pneumonia, acute pulmonary edema, renal failure, diabetes mellitus, neurological changes (central and psychosis, hypotension or septic shock, hepatitis, various cutaneous manifestations, hypothalamus-pituitary axis dysfunction, depression, multiple organ failure, symptoms that overlap with chronic phase toxoplasmosis. Thalidomide reduces increased cytokine levels. The present patent relates to a new use modality for thalidomide applied in chronic toxoplasmosis, which emphasizes the application of this drug based on the immunological technique in combination with antibiotic therapy, where the drug presents itself as an immunomodulator, reducing pathologically increased levels of cytokines, with normalization of the immune system and simultaneous treatment and / or prevention of serious and fatal complications, with minimal or no side effects. |
| priorityDate | 2002-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533589 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5426 |
Total number of triples: 14.